300199.SZ
翰宇药业
SZSE · Healthcare · C 制造业 · CN
CNY 22.17
−4.03%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
105.5x
Market Cap
CNY 19.58B
MomentumView details →
1D Return
−4.03%
YTD Return
+27.49%
RSI (14)
46.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
105.5x
Market Cap
CNY 19.58B
RSI (14)
46.8
MomentumView details →
1D Return
−4.03%
YTD Return
+27.49%
Similar companies
Latest newsMore news →
Hybio Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 237 million yuan, up 62.72% year-on-year; revenue was 688 million yuan, up 25.27% year-on-year.15d agoHanyu Pharmaceutical signed a cooperation agreement with Sansheng Mandi for semaglutide injection (blood glucose control indication).23d agoHybio Pharmaceutical signed a cooperation agreement with Sansheng Mandi regarding semaglutide injection.24d ago